Dystonia:治療薬パイプラインレビュー(2014年上半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC4912IDB)
◆英語タイトル:Dystonia - Pipeline Review, H1 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC4912IDB
◆発行日:2014年4月28日
◆調査対象地域:グローバル
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Dystonia:治療薬パイプラインレビュー(2014年上半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Dystonia – Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Dystonia – Pipeline Review, H1 2014’, provides an overview of the Dystonia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dystonia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Dystonia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dystonia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dystonia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dystonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dystonia Overview 6
Therapeutics Development 7
Pipeline Products for Dystonia – Overview 7
Pipeline Products for Dystonia – Comparative Analysis 8
Dystonia – Therapeutics under Development by Companies 9
Dystonia – Therapeutics under Investigation by Universities/Institutes 10
Dystonia – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Dystonia – Products under Development by Companies 13
Dystonia – Products under Investigation by Universities/Institutes 14
Dystonia – Companies Involved in Therapeutics Development 15
Ipsen S.A. 15
Addex Therapeutics 16
EpiVax, Inc. 17
QRxPharma Limited 18
Advicenne Pharma SA 19
Dystonia – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
abobotulinumtoxinA – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
dipraglurant – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ampicillin – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
T-9001 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
onabotulinumtoxinA – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ADV-6979 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Dystonia – Recent Pipeline Updates 36
Dystonia – Dormant Projects 40
Dystonia – Product Development Milestones 41
Featured News & Press Releases 41
Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 41
Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators 42
Apr 18, 2013: Addex’s Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1 42
Jan 29, 2013: Addex Therapeutics’s Dipraglurant Reduces Motor Abnormalities In Preclinical Model Of Dystonia 43
Oct 01, 2012: Allergan Comments on Order Regarding Permanent Injunction against Merz Pharmaceuticals and Merz Aesthetics 44
Apr 12, 2011: Merz’s XEOMIN Data To Be Presented At 63rd Annual Meeting Of American Academy Of Neurology 44
Sep 20, 2010: Merz Pharma Launches XEOMIN Patient Assistance Plan In Canada 45
Sep 07, 2010: MERZ Pharma’s XEOMIN Listed With Regular Benefit Status On AHWDBL 45
Aug 02, 2010: FDA Approves Merz Pharmaceuticals’ Xeomin (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm 46
Oct 29, 2009: Ipsen announces the launch of Dysport (abobotulinumtoxinA) in the United States for the treatment of cervical dystonia 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Number of Products under Development for Dystonia, H1 2014 7
Number of Products under Development for Dystonia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Dystonia - Pipeline by Ipsen S.A, H1 2014 15
Dystonia - Pipeline by Addex Therapeutics, H1 2014 16
Dystonia - Pipeline by EpiVax, Inc., H1 2014 17
Dystonia - Pipeline by QRxPharma Limited, H1 2014 18
Dystonia - Pipeline by Advicenne Pharma SA, H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Dystonia Therapeutics - Recent Pipeline Updates, H1 2014 36
Dystonia - Dormant Projects, H1 2014 40

List of Figures
Number of Products under Development for Dystonia, H1 2014 7
Number of Products under Development for Dystonia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28

*** 掲載企業 ***

Ipsen S.A.
Addex Therapeutics
EpiVax, Inc.
QRxPharma Limited
Advicenne Pharma SA

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 南アフリカSPAR :現地小売り企業分析
    Why was the report written? This is a comprehensive report covering SPAR’s operations in South Africa. It offers an insightful analysis of the company and details of its store formats, private labels, history, news, key employees, and key financial and operational metrics. The report also presents m …
  • 世界の農林業機械市場2016
    Notes:Production, means the output of Forestry Machinery Revenue, means the sales value of Forestry Machinery This report studies Forestry Machinery in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with prod …
  • 世界のオフィス文房具、備品、サービス市場動向(2012-2016)
    TechNavio's analysts forecast the Global Office Stationery, Supplies, and Services market to grow at a CAGR of 3.63 percent over the period 2012-2106. The increasing working population is one of the key factors contributing to this market growth. The Global Office Stationery, Supplies, and Services …
  • ReFood – Dagenham Waste-to-Energy Plant – London:建設プロジェクト概要
    World Market Intelligence's "ReFood – Dagenham Waste-to-Energy Plant – London - Construction Project Profile" is a crucial resource for industry executives and anyone looking to access key information about the ReFood – Dagenham Waste-to-Energy Plant – London construction project. World Market Intel …
  • 世界のロッカー市場2016
    Notes:Production, means the output of Locker Revenue, means the sales value of Locker This report studies Locker in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market sh …
  • ANA – Las Vegas All Net Arena and Resort: Hotel – Nevada:建設プロジェクト概要
    World Market Intelligence's "ANA – Las Vegas All Net Arena and Resort: Hotel – Nevada - Construction Project Profile" is a crucial resource for industry executives and anyone looking to access key information about the ANA – Las Vegas All Net Arena and Resort: Hotel – Nevada construction project. Wo …
  • アルメニアの写真撮影用カメラ市場(~2020):市場規模、動向、予測
    The report Photographic Camera Market in Armenia to 2020 - Market Size, Development, and Forecasts offers the most up-to-date industry data on the actual market situation, and future outlook for photographic cameras in Armenia. The research includes historic data from 2009 to 2015 and forecasts unti …
  • 世界の海洋性微細藻類抽出物市場2016
    Notes:Production, means the output of Marine Micro Algae Extractive Revenue, means the sales value of Marine Micro Algae Extractive This report studies Marine Micro Algae Extractive in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufact …
  • 脱毛剤(除毛剤)市場動向(~2017):オランダ
    Synopsis The report presents detailed data on consumption trends in the Depilatories category in Netherlands, analyzing consumption volumes and values at segment level. It also provides indispensable data on distribution channels along with latest industry news and mergers & acquisitions (of Skincar …
  • 世界及び中国の亜麻種子エキス市場2017
    The 'Global and Chinese Flax seed extract Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Flax seed extract industry with a focus on the Chinese market. The report provides key statistics on the market status of the Flax seed extrac …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC4912IDB )"Dystonia:治療薬パイプラインレビュー(2014年上半期)" (英文:Dystonia - Pipeline Review, H1 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。